{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:20:10Z","timestamp":1775222410415,"version":"3.50.1"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Talaris Therapeutics"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of the disease, diffuse cutaneous scleroderma (dcSSc), has no cure and limited treatment options. Haematopoietic stem cell transplantation has emerged as a potentially disease-modifying treatment but faces challenges such as toxicity associated with fully myeloablative conditioning and recurrence of autoimmunity. Novel cell therapies\u2014such as mesenchymal stem cells, chimeric antigen receptor-based therapy, tolerogenic dendritic cells and facilitating cells\u2014that may restore self-tolerance with more favourable safety and tolerability profiles are being explored for the treatment of dcSSc and other autoimmune diseases. This narrative review examines these evolving cell therapies.<\/jats:p>","DOI":"10.1093\/rheumatology\/keac628","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T17:14:16Z","timestamp":1668100456000},"page":"2060-2069","source":"Crossref","is-referenced-by-count":11,"title":["Improving outcomes in scleroderma: recent progress of cell-based therapies"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Krieger","sequence":"additional","affiliation":[{"name":"Talaris Therapeutics , Boston, MA and Louisville, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2023060113232034900_keac628-B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/reum.2019.87619","article-title":"Systemic sclerosis \u2013 multidisciplinary disease: clinical features and treatment","volume":"57","author":"Sobolewski","year":"2019","journal-title":"Reumatologia"},{"key":"2023060113232034900_keac628-B2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2023060113232034900_keac628-B3","doi-asserted-by":"crossref","first-page":"e0214202","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"2023060113232034900_keac628-B4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023060113232034900_keac628-B5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023060113232034900_keac628-B6","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113232034900_keac628-B7","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00296-017-3826-y","article-title":"Determinants of mortality in systemic sclerosis: a focused review","volume":"38","author":"Poudel","year":"2018","journal-title":"Rheumatol Int"},{"key":"2023060113232034900_keac628-B8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2023060113232034900_keac628-B9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023060113232034900_keac628-B10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023060113232034900_keac628-B11","first-page":"CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023060113232034900_keac628-B12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5301\/jsrd.5000250","article-title":"Mechanistic and clinical insights at the scleroderma-cancer interface","volume":"2","author":"Shah","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2023060113232034900_keac628-B13","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023060113232034900_keac628-B15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113232034900_keac628-B16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14728214.2020.1836156","article-title":"Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials","volume":"25","author":"Roofeh","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"2023060113232034900_keac628-B17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023060113232034900_keac628-B19","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","article-title":"Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American Society for Blood and Marrow Transplantation","volume":"24","author":"Sullivan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023060113232034900_keac628-B20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023060113232034900_keac628-B21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-015-0555-7","article-title":"Cell therapies in systemic sclerosis: recent progress","volume":"18","author":"van Rhijn-Brouwer","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2023060113232034900_keac628-B22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"2023060113232034900_keac628-B23","first-page":"23","article-title":"Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation","volume":"48","author":"Nelson","year":"1997","journal-title":"J Rheumatol Suppl"},{"key":"2023060113232034900_keac628-B24","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1073\/pnas.82.8.2483","article-title":"Rationale for bone marrow transplantation in the treatment of autoimmune diseases","volume":"82","author":"Ikehara","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023060113232034900_keac628-B25","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1073\/pnas.86.24.10090","article-title":"Regression of adjuvant-induced arthritis in rats following bone marrow transplantation","volume":"86","author":"van Bekkum","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023060113232034900_keac628-B26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"key":"2023060113232034900_keac628-B27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000531","article-title":"Application of stem cell transplantation in autoimmune diseases","volume":"26","author":"Ng","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"2023060113232034900_keac628-B28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","article-title":"CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023060113232034900_keac628-B29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2023060113232034900_keac628-B30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fimmu.2018.00767","article-title":"Resetting the T cell compartment in autoimmune diseases with autologous hematopoietic stem cell transplantation: an update","volume":"9","author":"Lutter","year":"2018","journal-title":"Front Immunol"},{"key":"2023060113232034900_keac628-B31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2015-06-649145","article-title":"Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells","volume":"127","author":"Delemarre","year":"2016","journal-title":"Blood"},{"key":"2023060113232034900_keac628-B32","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/art.39748","article-title":"Review: hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement","volume":"68","author":"Sullivan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B33","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1093\/rheumatology\/keab257","article-title":"Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients","volume":"60","author":"Lima-J\u00fanior","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113232034900_keac628-B34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"2023060113232034900_keac628-B35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/BOR.0000000000000541","article-title":"Hematopoietic stem-cell transplantation in systemic sclerosis: an update","volume":"30","author":"Spierings","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2023060113232034900_keac628-B36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"2023060113232034900_keac628-B37","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3389\/fimmu.2018.02390","article-title":"Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis","volume":"9","author":"Del Papa","year":"2018","journal-title":"Front Immunol"},{"key":"2023060113232034900_keac628-B38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"2023060113232034900_keac628-B39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"2023060113232034900_keac628-B40","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2023060113232034900_keac628-B41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023060113232034900_keac628-B42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2003.011205","article-title":"Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT\/EULAR Registry","volume":"63","author":"Farge","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023060113232034900_keac628-B43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42358-021-00166-8","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience","volume":"61","author":"Henrique-Neto","year":"2021","journal-title":"Adv Rheumatol"},{"key":"2023060113232034900_keac628-B44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023060113232034900_keac628-B45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.41519","article-title":"Association of autologous hematopoietic stem cell transplantation in systemic sclerosis with marked improvement in health-related quality of life","volume":"73","author":"Maltez","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review","volume":"59","author":"Puyade","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113232034900_keac628-B47","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"2023060113232034900_keac628-B48","doi-asserted-by":"crossref","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","article-title":"A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol","volume":"11","author":"Spierings","year":"2021","journal-title":"BMJ Open"},{"key":"2023060113232034900_keac628-B49","doi-asserted-by":"crossref","first-page":"100723","DOI":"10.1016\/j.adro.2021.100723","article-title":"Adverse effects of total body irradiation: a two-decade, single institution analysis","volume":"6","author":"Pearlman","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"2023060113232034900_keac628-B50","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"key":"2023060113232034900_keac628-B51","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/art.21908","article-title":"Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis","volume":"54","author":"Nash","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023060113232034900_keac628-B52","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2007.03.001","article-title":"Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect","volume":"13","author":"Van Wijmeersch","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023060113232034900_keac628-B53","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","article-title":"Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP working parties","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"2023060113232034900_keac628-B54","doi-asserted-by":"crossref","first-page":"e000533","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"2023060113232034900_keac628-B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","article-title":"Principles and overview of allogeneic hematopoietic stem cell transplantation","volume":"144","author":"Giralt","year":"2009","journal-title":"Cancer Treat Res"},{"key":"2023060113232034900_keac628-B56","doi-asserted-by":"crossref","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023060113232034900_keac628-B57","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2007-03-081596","article-title":"Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia","volume":"110","author":"Schrezenmeier","year":"2007","journal-title":"Blood"},{"key":"2023060113232034900_keac628-B58","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41584-019-0306-7","article-title":"Allogeneic HSCT for autoimmune disease: a shared decision","volume":"15","author":"Sullivan","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 5","key":"2023060113232034900_keac628-B59","doi-asserted-by":"crossref","first-page":"v18","DOI":"10.1093\/rheumatology\/ken267","article-title":"Mechanisms of vascular damage in SSc\u2014implications for vascular treatment strategies","volume":"47","author":"Guiducci","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2023060113232034900_keac628-B60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"2023060113232034900_keac628-B61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/BOR.0000000000000110","article-title":"Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy","volume":"26","author":"Castelino","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"2023060113232034900_keac628-B62","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"2023060113232034900_keac628-B63","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3389\/fimmu.2018.02938","article-title":"Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use?","volume":"9","author":"Rozier","year":"2018","journal-title":"Front Immunol"},{"key":"2023060113232034900_keac628-B64","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3389\/fimmu.2018.02013","article-title":"Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges","volume":"9","author":"Peltzer","year":"2018","journal-title":"Front Immunol"},{"key":"2023060113232034900_keac628-B65","doi-asserted-by":"crossref","first-page":"102755","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023060113232034900_keac628-B66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13619-020-00058-0","article-title":"Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives","volume":"9","author":"Abedi","year":"2020","journal-title":"Cell Regen"},{"key":"2023060113232034900_keac628-B67","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/art.42081","article-title":"Safety and efficacy of mesenchymal stromal cells and other cellular therapeutics in rheumatic diseases in 2022: a review of what we know so far","volume":"74","author":"Gilkeson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","article-title":"Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study","volume":"9","author":"Liang","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"2023060113232034900_keac628-B69","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.42133","article-title":"Adipose-derived regenerative cell transplantation in systemic sclerosis: scleroderma treatment with celution processed adipose derived regenerative cells: a randomized clinical trial","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08892-z","article-title":"Mesenchymal stem cell-based therapy as a new approach for the treatment of systemic sclerosis","author":"Zhuang","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023060113232034900_keac628-B71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T reg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023060113232034900_keac628-B72","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"2023060113232034900_keac628-B73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2023060113232034900_keac628-B74","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"2023060113232034900_keac628-B75","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"2023060113232034900_keac628-B76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"2023060113232034900_keac628-B77","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060113232034900_keac628-B78","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2023060113232034900_keac628-B79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"2023060113232034900_keac628-B80","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases?","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023060113232034900_keac628-B81","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/BOR.0b013e32835cb9f2","article-title":"Dendritic cell vaccination in autoimmune disease","volume":"25","author":"Gross","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2023060113232034900_keac628-B82","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"2023060113232034900_keac628-B83","doi-asserted-by":"crossref","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023060113232034900_keac628-B84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","article-title":"Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis","volume":"19","author":"Zhang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023060113232034900_keac628-B85","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023060113232034900_keac628-B86","first-page":"101","article-title":"Induction of donor-specific tolerance by transplantation of bone marrow","volume":"1","author":"Kaufman","year":"1994","journal-title":"Ther Immunol"},{"key":"2023060113232034900_keac628-B87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1074-7613(00)80133-8","article-title":"CD8+TCR+ and CD8+TCR-\u00a0cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers","volume":"11","author":"Gandy","year":"1999","journal-title":"Immunity"},{"key":"2023060113232034900_keac628-B88","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/ajt.13511","article-title":"Characterization of human CD8+TCR-\u00a0facilitating cells in vitro and in vivo in a NOD\/SCID\/IL2r\u03b3null mouse model","volume":"16","author":"Huang","year":"2016","journal-title":"Am J Transplant"},{"key":"2023060113232034900_keac628-B89","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/TP.0000000000000605","article-title":"Immune reconstitution\/immunocompetence in recipients of kidney plus hematopoietic stem\/facilitating cell transplants","volume":"99","author":"Leventhal","year":"2015","journal-title":"Transplantation"},{"key":"2023060113232034900_keac628-B90","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4049\/jimmunol.172.3.1463","article-title":"Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism","volume":"172","author":"Xu","year":"2004","journal-title":"J Immunol"},{"issue":"suppl 3","key":"2023060113232034900_keac628-B91","article-title":"Ten year follow-up of a Phase 2 clinical trial to induce tolerance in living donor renal transplant recipients [abstract]","volume":"19","author":"Leventhal","year":"2019","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"2023060113232034900_keac628-B92","article-title":"Long-term follow-up of a Phase 2 clinical trial to induce tolerance in living donor renal transplant recipients [abstract]","volume":"21","author":"Leventhal","year":"2021","journal-title":"Am J Transplant"},{"key":"2023060113232034900_keac628-B93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"2023060113232034900_keac628-B94","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023060113232034900_keac628-B95","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 131","key":"2023060113232034900_keac628-B96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.55563\/clinexprheumatol\/9ivp9g","article-title":"Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA","volume":"39","author":"Sankar","year":"2021","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac628\/47705617\/keac628.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2060\/50500648\/keac628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2060\/50500648\/keac628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:31:50Z","timestamp":1685626310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/6\/2060\/6820922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":96,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac628","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,11,10]]}}}